Study of the cytotoxic/toxic potential of the novel anticancer selenodiazoloquinolone on fibroblast cells and 3D skin model

Soňa JANTOVÁ 1, Dominika TOPOLSKÁ 1,2, Michaela JANOSKOVÁ 1, Miroslav PÁNIK 3, Viktor MILATA 4

1 Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, Slovakia
2 Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Bratislava, Slovakia
3 Institute of Management, Slovak University of Technology, Bratislava, Slovakia
4 Institute of Organic Chemistry, Catalysis and Petrochemistry, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, Slovakia

ABSTRACT

The new synthetically prepared quinolone derivative 7-ethyl 9-ethyl-6-oxo-6,9-dihydro[1,2,5]selenadiazolo[3,4-h]quinoline-7-carboxylate (E2h) showed in our previous study cytotoxic/toxic effects towards tumor cells and immunomodulatory activities on RAW 264.7 cell line murine macrophages. E2h may have a potential use as a novel chemotherapeutic agent with immunomodulatory properties and the ability to induce apoptotic death of cancer cells. The aim of the present study was to examine the antiproliferative/cytotoxic activities of E2h on human non-cancer fibroblast BHNF-1 cells and reconstructed human epidermis EpiDerm™. Further the effects of E2h on tissue structure and morphology were examined. Cytotoxic/toxic studies showed that selenadiazoloquinolone is not toxic on normal human fibroblast cells BHNF-1 and dimensional skin constructs EpiDerm™. Evaluation of morphological changes in EpiDerm™ showed no change in the construction and morphology of skin tissue treated by E2h compared to control.

KEY WORDS: quinolones; cytotoxicity; fibroblast BHNF-1 cells; EpiDerm™ viability; tissue morphology

Introduction

4-Quinolones (4-oxoquinolines) represent a group of heterocyclic compounds known for years. Many of them exhibited increased activity against bacteria and tumor cells in vitro and in vivo. Some of them are currently used worldwide in medical practice (e.g. ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin) (Blasi et al., 2006; Leibovitz, 2006; Hotinski et al., 2015). Several quinoline derivatives, as e.g. vosaroxin, dovitinib, tipifarnib, are currently explored in clinical practice as potential drugs for different hematologic malignancies or acute myeloid leukemia therapy.

Quinoline derivatives are multitarget agents with a variety of biological activities (Sharma et al., 2009; Chung et al., 2010; Darque et al., 2009; Santos et al., 2009; Sokolova et al., 2009; Meyer et al., 2007; Vinayaka et al., 2014; Huang et al., 1998; Oriel, 1998). Quinolines were shown to possess also antitumor and immunomodulatory activities (Tawfik et al., 1990; Xia et al., 2001; Riesbeck, 2002; Dalhoff & Shalit, 2003; Dalhoff, 2005; Drygin et al., 2009; You et al., 2009; Chou et al., 2009; Azema et al., 2009; George & Pili, 2013).

Quinoline derivatives are known as gyrase and topoisomerase I, II, and IV inhibitors, tubulin assembly inhibitors, farnesyltransferase inhibitors, P-glycoprotein inhibitors, protein kinase CK2 inhibitors, and photosystem II and cytochrome b6/f-complex inhibitors (Yamashita et al., 1992; Khodursky et al., 2001, Golub et al., 2007; Adams et al., 2007; Asoh et al., 2009).

Quinoline derivatives have cytotoxic/antiproliferative (Xiao et al., 2008; Foroumadi et al., 2009) and antimitotic activities (Chang et al., 2009). They are inducers of DNA damage, cell cycle arrest and apoptotic and autophagic cell death (Chang et al., 2009; Hadjeri et al., 2004; Sheng et al., 2008).

Based on the reported effects of quinoline derivatives, a new series of substituted selenadiazoloquinolones was prepared by Bella et al. (2010) and derivatives were screened for photochemical, antimicrobial and
cytotoxic/phototoxic activities in vitro. Some of these derivatives demonstrated biological activity.

The non-photoactivated and photoactivated 7-acetyl-6,9-dihydro-6-oxo-[1,2,5]selenadiazolo[3,4-h] quinoline (derivative E2h) exhibited the highest cytotoxicity/phototoxicity on selected cell lines (Jantová et al., 2010; Jantová et al., 2016a; Barbieriková et al., 2011a; 2011b; 2013). Detailed studies showed that E2h induced significant antiproliferative/cytotoxic activity on human lung carcinoma epithelial cells A549 and promyelocytic leukemia cells HL-60 and was found to be a potent inducer of apoptosis on leukemia cells. EPR studies showed that E2h behaved as a photosensitizer activating molecular oxygen upon photoexcitation and possessed sufficient photochemical stability under the given experimental conditions (Barbieriková et al., 2011b; Barbieriková et al., 2013). Our immunological studies showed immunomodulatory activities of selenadiazoloquinolone on RAW 264.7 cell line murine macrophages (Jantová et al., 2016b).

The obtained results indicate that selenadiazoloquinolone derivative E2h is a potential anticancer drug with immunomodulatory activities on topical administration. The aim of this work was to study the E2h cytotoxic/toxic potential on human non-cancer fibroblast BHNF-1 cells and human derived non-transformed epidermal keratinocyte model EpiDerm”.

Materials and methods

Material
DMSO was purchased from Merck (Slovakia). Trypan blue, thiazoyl blue tetrazolium bromide, phosphate buffered saline, penicillin and streptomycin were obtained from Sigma-Aldrich (Slovakia).

Dulbecco’s modified eagle medium (DMEM) was from Invitrogen (Germany), fetal bovine serum was from PAA Laboratories GmbH (Austria).

Quinolone derivative
The synthesized 7-ethyl 9-ethyl-6-oxo-6,9-dihydro-[1,2,5] selenadiazolo[3,4-h] quinoline-7-carboxylate (E2h, Scheme) was prepared by Bella et al. (2010). The stock solution of E2h was dissolved in 100% dimethylsulfoxide (DMSO), further diluted in the cell culture medium. Final concentration of DMSO added to cells did never exceed 0.1%.

Cell culture
Non-cancer human neonatal diploid cell line BHNF-1 (obtained from the collection of the Institute of Medical Biology, Genetics and Clinical Genetics, Comenius University in Bratislava, Slovakia) was used for cytotoxicity tests. These cells were grown at 37 °C in DMEM medium in humidified 5%-CO2 and 95%-air atmosphere. The medium was enriched with 10% (vol/vol) fetal calf serum, penicillin G (100 μg/mL) and streptomycin (100 μg/mL). Before a uniform monolayer of BHNF-1 cells was formed, cells were freed from the surface of the culture dish by a 0.25% solution of trypsin and were subcultivated two to three times a week. The cells were plated on Petri dishes (diameter 60 mm) at a density of 3 × 10^5–5 × 10^5 cells per mL of medium and incubated for 24 h prior to the experiments. Cell viability was determined by trypan blue exclusion tetradiazoloquinolone on fibroblasts and skin model.

3D human skin model
Reconstructed human three-dimensional skin constructs EpiDerm™ (EPI-200) were used for the toxicity test. The reconstructed human epidermis tissues (EpiDerm™) were obtained from MatTek Corp. (Bratislava, Slovakia). This in vitro model consists of normal, human-derived epidermal keratinocytes (NHEK) cultured at the air-liquid interface on a semi-permeable tissue culture insert. The NHEK cells form a multilayered, highly differentiated model of the human epidermis that consists of organized basal, spinous, granular, and cornified layers (stratum corneum), closely resembling native human epidermis.

Upon arrival, the EpiDerm™ tissues were transferred to 6-well plates (Sarstedt, Slovakia) containing 0.9 mL Maintenance Media (proprietary media provided by MatTek Co., and included with the tissues). The tissues were then equilibrated overnight at 37 °C, 5% CO2 in a humidified incubator prior to exposure to the test substances.

Growth inhibition assay
The inhibitory effects of cell proliferation by E2h were investigated by direct counting of the cell number in Bürker chamber, as described by Jantová et al. (2007). Before counting, the cells were stained with trypan blue dye (diluted 1:1 with cell suspension) to detect cell viability. The cells at a final density of 5 × 10^4 cells/mL were placed in Petri dishes (diameter 60 mm) overnight and treated with different concentrations of E2h (Scheme) for 24, 48 or 72 h. Final concentrations of the derivative added to the cells were in the range from 14 to 143 μM. Control cells were treated with DMSO, its final concentration never exceeding 0.1% (vol/vol). Negative control (NC) experiments were performed using DMSO-free cell systems.
The relative inhibition of cell proliferation or degeneration of a cell population was calculated as described by Letašiová et al. (2006).

After curve fitting, using nonlinear regression (Origin 7.0, Microcal), the IC_{50} values (the concentration resulting in 50% inhibition of the cell proliferation recorded in the control experiments) were determined separately for each experiment. The values were calculated from at least three independent experiments.

Chemical exposure of tissue model EpiDerm™

EPI-200 culture inserts were placed in 6-well plates and equilibrated with 0.9 mL of EPI-200-MM medium at 37°C. Following 1 h pre-incubation, the culture medium was replaced with fresh 0.9 mL of medium and skin cultures were placed on top of two stainless steel washers in 24-well plates. Tissues were treated by topically applying 50 μL of E2h derivative concentrations of 143 μM for 24, 48 and 72 h and at each time interval the culture medium and tissues were collected for analysis. Non-treated tissues were used as negative control, the tissue treated with 0.1% DMSO was used as control with dissolvent. Tissue samples were either used for the MTT tissue viability assay or harvested and stored in buffered formalin for histological analyses.

MTT tissue viability assay

The MTT assay (MTT-100, MatTek Corporation) was carried out as per manufacturer’s instructions. In brief, at the end of 24, 48 and 72 h of treatment, EPI-200 tissue samples were washed twice with PBS and placed in a fresh 24-well plate containing 300 μL/well of MTT solution.

After 3 h of incubation at 37°C, each insert was removed carefully, the bottom was blotted with paper wipes and the insert was transferred into a fresh 24-well plate. The culture inserts were then immersed in 2 mL/well of extraction solution (isopropanol). The plates were covered to reduce evaporation and incubated and shaken for 2 h at room temperature in the dark. After 2 h extraction, inserts were discarded and the contents of each well were mixed thoroughly before transferring 200 μL of the sample into 96-well plates. The optical density of the samples was read at 540 nm. Background readings for all the samples were determined at 740 nm and were subtracted to obtain the correct O.D. The % viability was determined for each tissue using the equation:

% Viability = 100 × [OD(sample)/OD(negative control)],

where OD is optical density.

| Cell line          | 24 h | 48 h | 72 h |
|--------------------|------|------|------|
| BHNF-1             | >143.0 | >143.0 | >143.0 |
| HeLa*              | 41.7±8.2 | 43.2±3.0 | 29.0±2.9 |
| HL-60*             | 55.0±5.0 | 28.0±1.8 | 27.0±2.1 |
| A549*              | 99.0±6.5 | 101.0±6.0 | 102.0±8.5 |

*In: Jantová et al., 2016a,b

Histological studies of tissue model

The EPI-200 cultures were collected at the end of the study and fixed in 10% neutral phosphate buffered formalin for at least 24 h at room temperature. Following fixation, the samples were dehydrated and embedded in paraffin. Five micrometer microtomed sections of the skin tissue samples were stained with hematoxylin and eosin according to common histological procedures (MatTek Corporation Protocol). The stained slides were examined under a Motic BA410 and assessed for histo-pathological changes associated with derivative exposure.

Statistical analysis

The individual data points from cell culture and 3D human skin model are presented as the means ± standard deviation (SD) of the mean of three separate experiments (each experiment was done with five parallels). The statistical significance of the results obtained from in vitro studies was evaluated by Student’s t-test, with probability values of 0.05 being considered significant.

Results

The results of the cytotoxic effects of selenaquinolone E2h (Scheme) measured by direct cell counting are shown in Figure 1. Different derivative concentrations in the range of 14.0–143 μM were added to the fibroblast BHNF-1 cells and cultivated for 24–72 h. As shown in the figure, derivative E2h did not manifest massive cytotoxic effect on normal fibroblast cells. We found only 25.2% growth inhibition after 72 h of BHNF-1 cells treated with the highest concentration tested (143 μM). The cells treated with the other concentrations tested (109, 71, 29 and 14 μM) grew comparably to non-treated control cells.

Table 1 shows the values of growth inhibitory concentrations IC_{50} of E2h. The values were obtained from the

**Figure 1.** Effect of E2h on proliferation of B-HNF-1 cells. The cells were cultured during 72 h in the absence or presence of E2h (concentrations in the range 14 - 143 μM). C – control cells treated with 0.1% DMSO. Cell proliferation was determined by direct counting in a counting chamber. Results were expressed as proliferation (cell number per dish) and represent mean ± SEM of three independent experiments, performed by triplicate.
Quinolone derivatives are currently explored clinically as potential drugs for different hematologic malignancies, acute myeloid leukemia, colon cancer or melanoma therapy (Thadepalli et al., 2005).

On the other hand, different sensitivities of non-cancer cells were found on quinolone treatment by some authors (Aranha et al., 2003; Xiao et al., 2008; Wang et al., 2008; Al-Trawneh et al., 2010; Huang et al., 2011; Forezi et al., 2014).

With the aim of obtaining new anticancer agents, a series of substituted quinolones, fluoroquinolones and selenadiazoloquinolones were prepared (Bella et al., 2014). Our previous experiments revealed some of these agents to be potent drugs towards microbial and cancer cells. The highest biological activity was caused by 7-ethyl 9-ethyl-6-oxo-6,9-dihydro [1,2,5]selenadiazolo[3,4-h] quinoline-7-carboxylate (E2h) on cancer cells.

Cytotoxic tests showed that derivative E2h evoked significant cytotoxic activity towards leukemia cell lines (L1210 and HL-60 cells), adenocarcinomic human alveolar basal epithelial cells A549 and cervical cancer cells HeLa (Jantová et al., 2016a,b). On the other hand, this agent did not display massive cytotoxicity on mouse non-cancer fibroblast cells NIH-3T3 (Jantová et al., 2010; Jantová et al., 2011; Barbieriková et al., 2011a; Barbieriková et al., 2011b; Barbieriková et al., 2013). Further we found that selenadiazoloquinolone E2h is inducer of apoptotic death of leukemia cells with immunomodulate properties on murine RAW 264.7 macrophages. E2h induced time- and concentration-dependent effective immunomodulation of pro- and anti-inflammatory cytokine release and antiproiferative/cytotoxic effect on RAW 264.7 cells (Jantová et al., 2016b). Our data show the E2h anticancer potential, suggesting its eventual application as chemotherapeutic drug.

This finding prompted us to study the effects of E2h on growth and viability of human non-cancer BHNF-1 cells and human derived non-transformed tissue model EpiDerm™. 3-D human skin culture (EpiDerm™) is a living reconstructed human epidermis used to provide information regarding the cytotoxicity, irritant potential and immunotoxicity of various compounds. In our study, we used the 3D skin model for toxicity observation of E2h, which could be topically administered in cervix adenocarcinoma and melanoma treatment.

As follows from the growth curves of fibroblast BHNF-1 (Figure 1), derivative E2h induced low antiproiferative effect, which even decreased with time. The cytotoxicity of the highest concentration of E2h tested was only 25.2% after 72 h of treatment.

On comparing the IC50 values as determined by the cell growth inhibition assay (Table 1) for non-cancer and cancer cell lines, it can be summarized that the least sensitive to E2h were human fibroblast BHNF-1 cells.

Our results are in accordance with the findings of many authors (Aranha et al., 2003; Xiao et al., 2008; Wang et al., 2008; Al-Trawneh et al., 2010; Huang et al., 2011; Forezi et al., 2014). Aranha et al. (2003) reported that ciprofloxacin showed antiproliferative and apoptosis inducing activity on prostate cancer cells but not on non-tumorigenic prostate epithelial cells. Xiao et al. (2008)

![Figure 2. Assessment of E2h skin toxicity. Toxicity of E2h (concentrations in the range 14 - 143 μM) was evaluated in the EpiDerm™ by the MTT assay after 24, 48 and 72 h incubation at 37°C. The fraction of epidermal cells remaining highly viable after 24, 48 and 72 h at 37°C was measured as the absorbance of formazan at 570 nm, subtracting a background reading for all samples at 650 nm with UV-visible spectrometer. Percentage of cell viability was determined at each of the concentration doses using the following formula: % viability = 100× (Abs570 - Abs650) of sample/(Abs570 - Abs650) of a control). Control was non-treated tissue and all data were normalized using data of control at 24, 48 and 72 h, and reported as mean ± SD. C-DMSO – tissue treated with 0.1 % DMSO.](image-url)
found that most of 3-aryl-1H-quinolin-4-one derivatives showed good cytotoxic activity against human cancer cell lines, but no cytotoxicity against a human normal cell line (L02). Selective cytotoxic activity of 2’-fluoro-6,7-methylenedioxy-2-phenyl-4-quinolone was reported by Wang et al. (2008). Quinolone induced growth inhibition of cancer HA22T, Hep3B, and HepG2 cells in a concentration-dependent manner but did not impair the viability of normal cells. Al-Trawneh et al. (2010) reported that five of 6-fluoro-4-oxopyrido[2,3-a]carbazole-3-carboxylic acids displayed growth inhibition against MCF-7 breast tumor and A549 non-small cell lung cancer cells coupled with the absence of cytotoxicity toward normal human-derm fibroblasts (HuDe). Huang et al. (2011) found that 2-(3-(methylamino) phenyl)-6-(pyrrolidin-1-yl) quinoline-4-one inhibited cell growth of leukemia cells in a dose-dependent manner. The derivative showed a much lower cytotoxic effect on normal HUVEC cells than on HL-60 cells. Also Forezi et al. (2014) reported that two derivatives from a series of 4-oxoquinolines displayed cytotoxicity against gastric cancer cell line but they did not display cytotoxicity at 20 μM on normal fibroblasts MRC-5.

3-D human skin culture (EpiDerm™) is a living reconstituted human epidermis used to provide information regarding the cytotoxicity, irritant potential and immunotoxicity of different compounds. In our study, we used this 3D skin model for assessing E2h toxicity. As seen in Figure 2, selenadiazoloquinolone E2h did not manifest toxic effects, with the percentage of cell viability in the range of 95-100.

EpiDerm™ tissue (EPI-200) obtained from MatTek Corporation is a multilayered, differentiated tissue consisting of basal, spinous, granular and cornified layers.
resembling normal human epidermis. The tissue is constructed from normal epidermal keratinocytes (foreskin-derived), which are cultured on chemically modified, collagen-coated, 9-mm (i.d.) cell culture inserts (e.g. Millicell CM or Nunc polycarbonate cell-culture inserts).

As seen in Figure 3, the control tissue and tissue treated with E2h (143 μM) consisted of non-damaged layers and no structural and morphological changes were found.

As follows from Table 1 and Figures 3 and 4, quinolone E2h did not manifest toxicity on human three-dimensional skin constructs EpiDerm™ and the highest derivative concentration of 143 μM did not induce significant morphologic damage in tissues.

In summary, we can conclude that the novel anticaner 7-ethyl 9-ethyl-6-oxo-6,9-dihydro[1,2,5] selenadiazolo [3,4-h] quinoline-7-carboxylate (E2h) which induces cytotoxic effects and apoptosis on human cancer cells is not toxic on human normal fibroblast cells BHNF-1 and human three-dimensional skin constructs EpiDerm™ and can thus be considered a potent chemotherapeutic drug.

**Acknowledgement**

The study was supported by the grants APVV-0038-11 and VEGA/ 1/0041/15.

**REFERENCES**

Adams M, Maharirger A, Kunert O, Fricker G, Effert T, Bauer R. (2007). Cytotoxicity and p-glycoprotein modulating effects of quinolones and indoloquinazolines from the Chinese herb Evodia rutaecarpa. Planta Med 73: 1554–1557.

Asoh K, Kohchi M, Hyouthu O, Ohtsuka T, Masubuchi M, Kawasaki K, Elibke H, Shiratori Y, Fukami T, Kondoh O, Tsukagushi I, Ishii N, Aoki Y, Shimmna N, Sakaitani M. (2009). Synthesis and structure-activity relationships of novel benzofuran farnesyltransferase inhibitors. Bioorg Med Chem Lett 19: 1753–1757.

Azena J, Guidetti B, Dewelle J, Le Calve B, Mijatovic T, Korolyov A, Vaysse J, Chang YT, Hsu MC. (2010). Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antiim- molation Agents Chemother 54: 411–417.

Jantová S, Letaliová S, Koňaríková K, Milata V, Brezová V. (2010). Effect of new synthetically prepared quinolone ethyl-1,4-dihydro-8-nitro-4-oxoquinoline-3-carboxylate on human leukemia cell line HL-60 with/without presence of UVA irradiation. Acta Chimica Slovaca 53: 1–72.

Jantová S, Koňaríková K, Letaliová S, Paulovičová E, Milata V, Brezová V. (2011). Photochemical and phototoxic properties of ethyl 1,4-dihydro-8-nitro-4-oxoquinoline-3-carboxylate, a new quinoline derivative. J Photochem Photobiol B - Biology 102: 77–91.

Jantová S, Mrvová N, Hudec R, Selačik J, Pánik M, Milata V. (2016a) Pro-apoptotic effect of new quinolone 7-ethyl 9-ethyl-6-oxo-6,9-dihydro[1,2,5] selenadiazolo[3,4-h]quinoline-7-carboxylate on cervical cancer cell line HeLa alone/with UVA irradiation. Toxicol in Vitro 33: 35–44.

Jantová S, Paulovičová E, Paulovičová L, Topolská D, Pánik M, Milata V. (2016b) The effects of novel selenadiazoloquinolone derivative on cancer cell proliferation, apoptosis and immunomodulatory activities. Cell Biol Toxicol (Accepted in Press).

Khodursky A, Zechiedrich E, Cazzarelli N. (1995). Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Nat Acad Sci USA 92: 11801–11805.

Letaliová S, Jantová S, Čipák L, Múčková M. (2006). Berberine—antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett 239: 254–262.

Medeiros B, Landau H, Morrow M, Lockerbie R, Pitts T, Eckhardt S. (2007). The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia 21(4): 739–46.

Meyer E, Schwab F, Gastmeier P, Ruden H, Heiningen A. (2007). Antifungal use in intensive care units. J Antimicrob Chemother 61: 619–624.

Oriol J. (1989). Use of quinolones in chlamydial infection. Rev Infect Dis 11: 51273–51276.

Riesbeck K. (2002). Immunomodulating activity of quinolones: review. J Chemother 14: 3–12.

Santos F, Abreu P, Castro H, Paixão I, Círino-Santos C, Giongo V, Barbosa J, Simonetti B, Garrido V, Bou-Habib D, Silva D, Batalha P, Temerzo J, Souza T, Nogueira C, Cunha A, Rodrigues C, Ferreira V, de Souza M. (2009). Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives. Bioorg Med Chem 17: 5476–5481.

Copyright © 2016 SETOX & Institute of Experimental Pharmacology and Toxicology, SASc.
Sharma PC, Jain A, Jain S. (2009). Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. *Acta Pol Pharm* **66**: 587–604.

Sheng Z, Cao X, Peng S, Wang C, Li Q, Wang Y, Liu M. (2008). Ofloxacin induces apoptosis in microencapsulated juvenile rabbit chondrocytes by caspase-8-dependent mitochondrial pathway. *Toxicol Appl Pharmacol* **226**: 119–127.

Sokolova G, Kunichan AD, Lazareva YV. (2009). Levofloxacin (Tavanic) in complex therapy of tuberculosis. *Antibiot Khimioter* **54**: 31–37.

Tawfi k AF, Shoeb HA, Bishop SJ, Al-Shammary FJ, Shbl AM. (1990). Influence of new quinolones on normal immune capabilities. *J Chemother* **2**: 300–3005.

Vinayaka AC, Sadashiva MP, Wu X, Biryukov SS, Stoute JA, Rangappa KS, Gowda DC. (2014). Facile synthesis of antimarial odiazoloquinolone on fibroblasts and skin model 1,2-disubstituted 4-quinolones from 1,3-bisaryl-monothio-1,3-diketones. *Org Biomol Chem* **12**: 8555–8561.

Xia Y, Yang Z, Xia P, Hackl T, Hamel E, Mauger A, Wu J, Lee K. (2001). Antitumoragents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antmitotic antitumor agents. *J Med Chem* **44**: 3932–3936.

Xiao ZP, Li HQ, Shi L, Lv PC, Song ZC, Zhu HL. (2008). Synthesis, antiproliferative activity, and structure-activity relationships of 3-aryl-1H-quinolin-4-ones. *Chem Med Chem* **3**: 1077–1082.

Yamashita Y, Ashizawa T, Morimoto M, Hosomi J, Nakano H. (1992). Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. *Cancer Res* **52**: 2818–2822.

You Q, Li Z, Huang C, Yang Q, Wang X, Guo Q, Chen X, He X, Li T, Chern J. (2009). Discovery of a novel series of quinoline and naphthyridine derivatives as potential topoisomerase I inhibitors by Scaffold modification. *J Med Chem* **52**: 5649–5661.